Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Itraconazole + LY4170156 |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Itraconazole | Hyphanox | ITC | mTOR Inhibitor 51 | Itraconazole is an antifungal, which indirectly targets mTOR (PMID: 20176935). |
| LY4170156 | LY-4170156|LY 4170156 | FOLR1-targeted Therapy 24 | LY4170156 is an antibody-drug conjugate (ADC) comprising a monoclonal antibody against FOLR1 (folate receptor alpha; FRa) linked to the topoisomerase I inhibitor exatecan, which may induce apoptosis and inhibit proliferation of tumor cells expressing FOLR1 (FRa) (J Clin Oncol (2024) 42:16_suppl, 3023, NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06400472 | Phase I | Bevacizumab + LY4170156 LY4170156 + Pembrolizumab Carboplatin + LY4170156 LY4170156 Itraconazole + LY4170156 | A Study of LY4170156 in Participants With Selected Advanced Solid Tumors | Recruiting | USA | ITA | FRA | ESP | AUS | 2 |